KR20250006238A - 안구 질환을 치료하기 위한 조성물 및 방법 - Google Patents

안구 질환을 치료하기 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20250006238A
KR20250006238A KR1020247039210A KR20247039210A KR20250006238A KR 20250006238 A KR20250006238 A KR 20250006238A KR 1020247039210 A KR1020247039210 A KR 1020247039210A KR 20247039210 A KR20247039210 A KR 20247039210A KR 20250006238 A KR20250006238 A KR 20250006238A
Authority
KR
South Korea
Prior art keywords
antibody
amino acid
seq
acid sequence
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247039210A
Other languages
English (en)
Korean (ko)
Inventor
테드 야드녹
로리 테일러
아니타 그로버
도널드 퐁
Original Assignee
애넥슨, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 애넥슨, 인코포레이티드 filed Critical 애넥슨, 인코포레이티드
Publication of KR20250006238A publication Critical patent/KR20250006238A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020247039210A 2022-04-29 2023-04-28 안구 질환을 치료하기 위한 조성물 및 방법 Pending KR20250006238A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263336539P 2022-04-29 2022-04-29
US63/336,539 2022-04-29
PCT/US2023/066393 WO2023212719A1 (en) 2022-04-29 2023-04-28 Compositions and methods for treating ocular diseases

Publications (1)

Publication Number Publication Date
KR20250006238A true KR20250006238A (ko) 2025-01-10

Family

ID=88519880

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247039210A Pending KR20250006238A (ko) 2022-04-29 2023-04-28 안구 질환을 치료하기 위한 조성물 및 방법

Country Status (10)

Country Link
US (1) US20250313614A1 (cg-RX-API-DMAC7.html)
EP (1) EP4518896A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025515485A (cg-RX-API-DMAC7.html)
KR (1) KR20250006238A (cg-RX-API-DMAC7.html)
CN (1) CN119136830A (cg-RX-API-DMAC7.html)
AU (1) AU2023262202A1 (cg-RX-API-DMAC7.html)
CA (1) CA3250843A1 (cg-RX-API-DMAC7.html)
IL (1) IL316218A (cg-RX-API-DMAC7.html)
MX (1) MX2024013326A (cg-RX-API-DMAC7.html)
WO (1) WO2023212719A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025184235A1 (en) * 2024-02-28 2025-09-04 Onl Therapeutics, Inc. Methods and compositions for treating glaucoma

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8148330B2 (en) * 2005-12-09 2012-04-03 The Board Of Trustees Of The Leland Stanford Junior University Modulation of synaptic maintenance
DK1991275T3 (en) * 2006-03-08 2014-12-08 Archemix Llc Complement aptamers AND ANTI-C5 AGENTS FOR USE IN THE TREATMENT OF EYE DISEASES
FI3380518T3 (fi) * 2015-11-24 2026-05-29 Annexon Inc Antikomplementtitekijä-C1Q:n Fab-fragmentteja ja niiden käyttöjä
CN116782940A (zh) * 2020-12-04 2023-09-19 安尼艾克松股份有限公司 用于治疗眼部疾病的组合物和方法

Also Published As

Publication number Publication date
AU2023262202A1 (en) 2024-10-24
US20250313614A1 (en) 2025-10-09
JP2025515485A (ja) 2025-05-15
IL316218A (en) 2024-12-01
WO2023212719A1 (en) 2023-11-02
CN119136830A (zh) 2024-12-13
EP4518896A1 (en) 2025-03-12
EP4518896A4 (en) 2026-08-12
CA3250843A1 (en) 2023-11-02
MX2024013326A (es) 2024-12-06

Similar Documents

Publication Publication Date Title
US20250002567A1 (en) Anti-complement factor c1q fab fragments and uses thereof
JP7499760B2 (ja) 脳損傷を治療するための組成物及び方法
AU2007329759B2 (en) Compositions and methods for binding sphingosine-1-phosphate
US20240059765A1 (en) Compositions and methods for treating ocular diseases
JP2009280626A (ja) 眼疾患を処置するための補体経路の阻害剤の使用
KR20190005944A (ko) 척수성 근위축 치료용 조성물 및 방법
JP2020519634A (ja) 移植片拒絶の予防に使用するための抗cd40抗体
CA3030872A1 (en) Compositions and methods for treating frontotemporal dementia
JP2026028257A (ja) 血液障害を処置するための組成物及び方法
US20250313614A1 (en) Compositions and methods for treating ocular diseases
WO2023070087A1 (en) Compositions and methods for treating muscular dystrophy
HK40121733A (en) Compositions and methods for treating ocular diseases
EA050212B1 (ru) Композиции и способы лечения болезней глаз
HK40101076A (en) Compositions and methods for treating ocular diseases
KR20260052059A (ko) 소변 uC5b-9 검출에 기반한 국소 보체 억제를 통한 보체-매개 질환의 표적 치료
CA3006092C (en) Anti-complement factor c1q fab fragments and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P12-X000 Request for amendment of application rejected

St.27 status event code: A-2-2-P10-P12-nap-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000